Gyre Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

• Gyre Therapeutics Inc GYRE.OQ reported quarterly adjusted earnings of 3 cents​​ per share for the quarter ended March 31. The lone analyst forecast for the quarter was for earnings of 3 cents per share.

• Revenue was $22.06 million​; analysts expected $28.40 million.

• Gyre Therapeutics Inc's reported EPS for the quarter was breakeven results​.

• The company reported quarterly net income of $2.7 million.

• Gyre Therapeutics Inc shares had risen by 22.8% this quarter and lost 21.7% so far this year.

FORECAST CHANGES

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Gyre Therapeutics Inc is $20.00

This summary was machine generated from LSEG data May 9 at 11:19 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)